Immune Checkpoint Inhibitors | Current Treatment | Real World Brand Tracker

Publish date: July 2019

Login to access report

Driven by DRG’s oncology expertise and real-world data capabilities, the Real World Brand Tracker is an interactive dashboard of regularly updated U.S. claims data that monitors and highlights the shifting market dynamics and the impact of events on immune checkpoint inhibitor prescribing.

QUESTIONS ANSWERED

How is the uptake for individual brands changing over time and across different U.S. regions and individual states?

Which brand is winning, and how does that vary by indication?

How does the dynamic regulatory environment for immune checkpoint inhibitor brands in the United States affect prescribing patterns of currently approved brands by indication?

What is the average claim charge for each brand? How does this compare to the reimbursed amount? How does each of these metrics vary by payer type?

In which types of facilities are patients receiving these brands?

KEY BENEFITS AND USES

Understand evolving market dynamics and correlate clinical and regulatory events to brand use by indication.

Track number of patients treated with immune checkpoint inhibitor brands over time.

Segment the data in multiple ways, including by state and treatment setting, to reveal pockets of opportunity.

Visualize trends in payer metrics including total claim amount, total claim paid, and top payers for immune checkpoint inhibitors.

Design appropriate clinical trial strategies based on rapidly evolving standards in treatment practices, as revealed by claims data.

Uncover pockets of opportunity for improved penetration and identify segments where brands are performing poorly.

Table of contents

  • Real World Brand Tracker
    • Dashboard Access
      • Dashboard Access

Author(s): Paul Wilcock. PhD

Since October 2015, Dr. Wilcock has been a Business Insights Analyst in the oncology team at Decision Resources Group. He has experience in various indications including metastatic malignant melanoma and renal cell carcinoma, and will have a major focus on gastric cancer going forward. Previously, Dr. Wilcock was a Research Funding Manager at Cancer Research UK, where he developed a deep understanding of drug discovery, predominantly in the academic setting. He gained his doctorate from the University of Manchester where he utilized Systems Biology to explore the role of cell signaling and hypoxia in oral cancer.